The protocol for the HR-NBL-2 (High Risk Neuroblastoma) has been approved by the SIOPEN Group and will now be submitted to the ethics committee. Up to 1000 patients can be expected to enrol in the next 5-7 years. All patients will receive radiotherapy and the QUARTET Platform will be used for prospective quality assurance. The aim is to start enrolling patients at the end of the year. Two other trials, FaR-RMS (Rhadomyosarcoma) and PNET-5 (Medulloblastoma) should start prospective quality assurance via the QUARTET Platform by the end of this year. More information here.